CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Ultragenyx Q3 revenue rises, net loss narrows

By Reuters News


Overview

  • US biopharmaceutical firm's Q3 revenue rose to $173 mln from $160 mln a year earlier

  • Net loss narrowed to $118 mln from $180 mln in Q3 2025


Outlook

  • Ultragenyx reaffirms 2026 total revenue guidance of $730 mln to $760 mln

  • Company maintains 2026 Crysvita revenue guidance at $500 mln to $520 mln

  • Company expects to achieve full-year GAAP profitability in 2027


Result Drivers

  • NEW PRODUCT LAUNCHES - Co said launches of newly approved gene therapies GENGLYCOS and FAYUVI are progressing well with growing demand

  • EVKEEZA DEMAND - Increased demand from new country launches and early access drove EVKEEZA revenue


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$1.16

Q3 Net Loss

$118 mln

Q3 Operating Expenses

$283 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc. is $25.00, about 53.4% above its November 2 closing price of $16.30


Reuters Recommended Reads

  • Nov 2 - BioMarin Q3 revenue rises on Amicus acquisition, adjusted EPS beats

  • Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

  • Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.